Mallinckrodt Provides Additional Information on Dutch High-Flux Reactor

December 21, 2012

Mallinckrodt, the Pharmaceutical business of Covidien, has provided additional information regarding the delayed return to operation for the Dutch High-Flux Reactor (HFR).  Mallinckrodt has been informed that the reactor will not restart in December.

For more information, please find the letter below.

 

Mallinckrodt Letter